These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27579329)

  • 21. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs].
    Saitoh S
    Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.
    Ulrich P; Blaich G; Baumann A; Fagg R; Hey A; Kiessling A; Kronenberg S; Lindecrona RH; Mohl S; Richter WF; Tibbitts J; Crameri F; Weir L
    Regul Toxicol Pharmacol; 2018 Apr; 94():91-100. PubMed ID: 29355662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.
    Blaich G; Baumann A; Kronenberg S; de Haan L; Ulrich P; Richter WF; Tibbitts J; Chivers S; Tarcsa E; Caldwell R; Crameri F
    Regul Toxicol Pharmacol; 2016 Oct; 80S():S1-S14. PubMed ID: 27578450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics.
    Baker M; Carr F
    Curr Drug Saf; 2010 Oct; 5(4):308-13. PubMed ID: 20615174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of immunogenic response to protein therapeutics.
    Singh SK; Cousens LP; Alvarez D; Mahajan PB
    Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.
    Wakshull E; Quarmby V; Mahler HC; Rivers H; Jere D; Ramos M; Szczesny P; Bechtold-Peters K; Masli S; Gupta S
    AAPS J; 2017 Nov; 19(6):1656-1668. PubMed ID: 28795351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for the preclinical and clinical characterization of immunogenicity.
    Koren E; Mytych D; Koscec M; Ferbas J; Gupta S; Moxness M; Swanson S
    Dev Biol (Basel); 2005; 122():195-200. PubMed ID: 16375262
    [No Abstract]   [Full Text] [Related]  

  • 28. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.
    Carrascosa JM; van Doorn MB; Lahfa M; Nestle FO; Jullien D; Prinz JC
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1424-30. PubMed ID: 24841895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.
    Barbosa MD
    Drug Discov Today; 2011 Apr; 16(7-8):345-53. PubMed ID: 21300174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dealing with immunogenicity of biologicals: assessment and clinical relevance.
    Wolbink GJ; Aarden LA; Dijkmans BA
    Curr Opin Rheumatol; 2009 May; 21(3):211-5. PubMed ID: 19399992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.
    van Eden W; Lisse J; Prakken B; Albani S
    Drug Discov Today; 2010 Jan; 15(1-2):71-7. PubMed ID: 19162218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.
    Kintzing JR; Filsinger Interrante MV; Cochran JR
    Trends Pharmacol Sci; 2016 Dec; 37(12):993-1008. PubMed ID: 27836202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.
    Shah DK
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):553-71. PubMed ID: 26373957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonclinical immunogenicity risk assessment of therapeutic proteins.
    Tourdot S; Hickling TP
    Bioanalysis; 2019 Sep; 11(17):1631-1643. PubMed ID: 31208200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
    Hamuro L; Kijanka G; Kinderman F; Kropshofer H; Bu DX; Zepeda M; Jawa V
    J Pharm Sci; 2017 Oct; 106(10):2946-2954. PubMed ID: 28576695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.